Jefferies Maintains Hold on Mineralys Therapeutics, Raises Price Target to $26
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $15 to $26.
Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $15 to $26.